S&P 500   3,328.09 (+0.01%)
DOW   27,233.95 (+0.12%)
QQQ   271.69 (+0.24%)
AAPL   446.60 (+1.44%)
MSFT   213.02 (+0.04%)
FB   261.79 (+5.09%)
GOOGL   1,491.22 (+0.82%)
AMZN   3,194.20 (-0.34%)
NVDA   449.88 (-0.35%)
CGC   18.22 (-5.15%)
BABA   261.04 (-1.46%)
TSLA   1,491.09 (+0.41%)
MU   48.80 (-4.41%)
GE   6.34 (-0.94%)
AMD   85.98 (+0.79%)
T   29.80 (-0.17%)
F   6.94 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.80 (-0.29%)
NFLX   502.96 (+0.17%)
DIS   129.02 (+1.10%)
BAC   25.44 (+0.20%)
BA   173.38 (-0.52%)
S&P 500   3,328.09 (+0.01%)
DOW   27,233.95 (+0.12%)
QQQ   271.69 (+0.24%)
AAPL   446.60 (+1.44%)
MSFT   213.02 (+0.04%)
FB   261.79 (+5.09%)
GOOGL   1,491.22 (+0.82%)
AMZN   3,194.20 (-0.34%)
NVDA   449.88 (-0.35%)
CGC   18.22 (-5.15%)
BABA   261.04 (-1.46%)
TSLA   1,491.09 (+0.41%)
MU   48.80 (-4.41%)
GE   6.34 (-0.94%)
AMD   85.98 (+0.79%)
T   29.80 (-0.17%)
F   6.94 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.80 (-0.29%)
NFLX   502.96 (+0.17%)
DIS   129.02 (+1.10%)
BAC   25.44 (+0.20%)
BA   173.38 (-0.52%)
S&P 500   3,328.09 (+0.01%)
DOW   27,233.95 (+0.12%)
QQQ   271.69 (+0.24%)
AAPL   446.60 (+1.44%)
MSFT   213.02 (+0.04%)
FB   261.79 (+5.09%)
GOOGL   1,491.22 (+0.82%)
AMZN   3,194.20 (-0.34%)
NVDA   449.88 (-0.35%)
CGC   18.22 (-5.15%)
BABA   261.04 (-1.46%)
TSLA   1,491.09 (+0.41%)
MU   48.80 (-4.41%)
GE   6.34 (-0.94%)
AMD   85.98 (+0.79%)
T   29.80 (-0.17%)
F   6.94 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.80 (-0.29%)
NFLX   502.96 (+0.17%)
DIS   129.02 (+1.10%)
BAC   25.44 (+0.20%)
BA   173.38 (-0.52%)
S&P 500   3,328.09 (+0.01%)
DOW   27,233.95 (+0.12%)
QQQ   271.69 (+0.24%)
AAPL   446.60 (+1.44%)
MSFT   213.02 (+0.04%)
FB   261.79 (+5.09%)
GOOGL   1,491.22 (+0.82%)
AMZN   3,194.20 (-0.34%)
NVDA   449.88 (-0.35%)
CGC   18.22 (-5.15%)
BABA   261.04 (-1.46%)
TSLA   1,491.09 (+0.41%)
MU   48.80 (-4.41%)
GE   6.34 (-0.94%)
AMD   85.98 (+0.79%)
T   29.80 (-0.17%)
F   6.94 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.80 (-0.29%)
NFLX   502.96 (+0.17%)
DIS   129.02 (+1.10%)
BAC   25.44 (+0.20%)
BA   173.38 (-0.52%)
Log in

OTCMKTS:DNDNQDendreon Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:DNDNQ
Previous SymbolNASDAQ:DNDN
CUSIPN/A
CIKN/A
Phone+1-206-2197815

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive DNDNQ News and Ratings via Email

Sign-up to receive the latest news and ratings for DNDNQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dendreon (OTCMKTS:DNDNQ) Frequently Asked Questions

How were Dendreon's earnings last quarter?

Dendreon Co. (OTCMKTS:DNDNQ) released its earnings results on Monday, November, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biotechnology company earned $73.10 million during the quarter, compared to the consensus estimate of $78.72 million. The firm's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.44) earnings per share.
View Dendreon's earnings history
.

Has Dendreon been receiving favorable news coverage?

News headlines about DNDNQ stock have trended very negative on Thursday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dendreon earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Dendreon
.

What is Dendreon's stock symbol?

Dendreon trades on the OTCMKTS under the ticker symbol "DNDNQ."

How do I buy shares of Dendreon?

Shares of DNDNQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dendreon's official website?

The official website for Dendreon is www.dendreon.com.

How can I contact Dendreon?

Dendreon's mailing address is 601 Union St Ste 4900, SEATTLE, WA 98101-3906, United States. The biotechnology company can be reached via phone at +1-206-2197815.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.